Global Markets for Hyaluronic Acid Viscosupplementation

Millennium Research Group
December 31, 2010
SKU: MIL6655143
License type:
Table of Contents Related Reports
Countries covered: Global

Introduction:

In 2010, the global market for hyaluronic acid (HA) viscosupplementation was valued at nearly $1.4 billion. The US maintained both the largest and fastest-growing market for HA viscosupplementation in 2010. Japan, the second-largest market globally, experienced a slight loss in market revenues in 2010 as a result of continuing biennial reimbursement cuts despite growth in treatment volumes that will continue steadily through 2015. The European market and emerging markets of Brazil, India, and China (BIC) together represent a significantly smaller portion of the global market; market revenue in both regions will grow, however, as a result of rising treatment volumes and the adoption of premium-priced products in many countries in these regions. Demand for HA viscosupplementation treatment volumes will also be fueled worldwide by the aging global population, which is more susceptible to osteoarthritis, the primary condition that requires HA viscosupplementation treatment. Moreover, rising obesity rates in most regions are also contributing to growing osteoarthritis prevalence rates, further raising demand for treatments. Increasing patient and physician awareness of the benefits of HA viscosupplementation compared to alternative treatments for osteoarthritis pain, such as nonsteroidal anti-inflammatory drugs or cyclooxygenase-2 inhibitors, is also helping to expand treatment volumes. While intense price competition and unfavorable reimbursement policies in many of the countries covered will limit average selling prices (ASPs), a trend toward shorter treatment regiments using premium-priced 3- and 1-injection products will contribute to overall increases in ASPs through 2015. Globally, the HA viscosupplementation market will experience strong growth over the forecast period.

Questions Answered in This Report:
  • In Europe, premium-priced 1- and 3-injection HA viscosupplementation products are becoming more popular because convenience has become a more important point of consideration compared to pricing for many patients. How will the adoption rate of 1-injection products differ across the various European countries? What are companies in the 3-injection and 5-injection segments doing to remain competitive? What is the outlook for the overall European HA viscosupplementation market over the course of the forecast period?
  • In the US, premium-priced 1-injection HA viscosupplementation products will be increasingly adopted over the forecast period. Will both 3- and 5-injection products be equally impacted? What is the expected impact of the introduction of other 1-injection products, such as Zimmer's Gel-200 and DePuy Mitek's MONOVISC? Will Smith & Nephew's Durolane enter the market before 2015?
  • In Japan, contrary to the previously expected trend, the percentage of treatments performed using brand name HA viscosupplementation products instead of generic competing products will slightly increase as a result of physician and patient preference for brands with strong established reputations. How are manufacturers of generic products responding to limited market share growth? How will the introduction of Genzyme's Synvisc 3-injection product (the first non-domestic and non-5-injection product available in Japan) affect the well-established and highly competitive Japanese market? What will the net effect on Japanese ASPs be from the shift in product mix? How will this impact the value of the Japanese HA viscosupplementation market?
  • In BIC, HA viscosupplementation is still a relatively new method of treatment; many physicians still look to administer alternative treatments, such as a combination of chondroitin and glucosamine in Brazil, ayurvedic practices in India, or traditional Chinese medicine in China. Nonetheless, following the introductions of well-recognized foreign brands within the past year with strong track records of safety and efficacy, physician awareness and confidence in HA viscosupplementation products will grow. Which country will show the strongest revenue growth moving into 2015 and why? How will the introduction and adoption of 1-injection products affect revenue growth across each HA viscosupplementation market? How will the lack of a 1-injection market in China affect its market size compared to Brazil and India?
Scope:

Regions covered: US, Europe (France, Germany, Italy, Spain, UK), Japan, Brazil, India, China

Procedure segmentation: Our analysis uses the following breakdown of procedures:
  • US
  • By segment (1-injection, 3-injection, and 5-injection)
  • By application (knee, shoulder, hip, and other)
  • By site (sports medicine clinic, rheumatology clinic, primary care clinic, and other)
  • Europe
  • By segment (1-injection, 3-injection, and 5-injection)
  • By application (knee, shoulder, hip, other)
  • Japan
  • By segment (1-injection, 3-injection, and 5-injection)
  • By application (knee, shoulder, hip, and other)
  • By type (brand name and generic)
  • BIC
  • By segment (1-injection, 3-injection, and 5-injection)
  • By application (knee, shoulder, hip, and other)
Market segmentation: Our analysis uses the following breakdown of the market:
  • US
  • Europe
  • By segment (1-injection, 3-injection, and 5-injection)
  • Japan
  • By segment (1-injection, 3-injection, and 5-injection)
  • By type (brand name and generic)
  • BIC
  • By segment (1-injection, 3-injection, and 5-injection)
Market forecast features: Based on primary research with industry professionals, we use our proprietary forecasting model to provide an in-depth examination of current and future trends in procedure volumes, average selling prices, and market values over a 7-year period (2009-2015).

Competitive analysis: We provide a detailed analysis of the competitive landscape in the market, as well as market shares and qualitative discussions of the leading competitors in each market segment.


More Global Medical Devices Reports

The Global Market for Medical Devices, 3rd. Edition by Kalorama Information
Medical device makers faced a productive but challenging year in 2011. They innovated existing lines, launched new devices and invested in R&D.  But they ...

Biopsy Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018 by GlobalData
Biopsy Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018 Summary GlobalData’s new report, “Biopsy Devices - Global Pipeline Analysis, Competitive Landscape and Market ...

2011 Global Social Media in the Medical Devices Industry by Frost & Sullivan
This study’s research objective is to gauge social media usage within the medical devices industry. The data was collected in October 2011, using web-based surveys. ...

The Guide to Distributors of Medical Equipment & Supplies Worldwide 2012 by Espicom Healthcare Intelligence
Helping you achieve cost-effective sales and wider distribution for your medical products worldwide! Updated daily on the web or in regional print editions.

The Guide to Distributors of Medical Equipment & Supplies Worldwide 2012 Volume IV:Asia/Pacific by Espicom Healthcare Intelligence
426 specialist medical sales companies in 22 countries from Australia and Bangladesh to Thailand and Vietnam These days we must all work harder to ...

See all reports like this >>

 

Share this report


Other tasks

 
 

Research Assistance

Ask a question
 

Related Markets


Medical Devices Reports

 
 

Free Alert Me service

Receive bi-weekly email alerts on new market research

Sign Up Today!